Medical marijuana is not covered by health insurance in the United States. No major private insurer, Medicare, Medicaid, or Veterans Affairs plan will pay for cannabis purchased at a dispensary, regardless of whether your state has legalized it. The reason comes down to a single fact: marijuana remains a federally controlled substance, and insurers follow federal law when deciding what to reimburse.
That said, a small number of FDA-approved medications derived from cannabis compounds are covered by some plans. Understanding the distinction between dispensary cannabis and these prescription drugs can save you time and help you budget for what will likely be an entirely out-of-pocket expense.
Why Federal Law Blocks Coverage
Marijuana is classified as a Schedule I substance under the Controlled Substances Act, the same category as heroin and LSD. Schedule I means the federal government considers it to have no currently accepted medical use, even though 38 states and Washington, D.C., have passed their own medical marijuana laws. Insurance companies, including those that operate across state lines, base their formularies on federal drug scheduling and FDA approval. A drug that the federal government says has no accepted medical use simply cannot appear on an insurer’s list of covered medications.
This applies across the board. Private insurers like Blue Cross, Aetna, and UnitedHealthcare do not cover it. Medicare Part D does not cover it. State Medicaid programs do not cover it. The Department of Veterans Affairs is especially explicit: VA pharmacies may not fill prescriptions for medical marijuana, VA clinicians may not recommend it, and VA staff may not even complete the paperwork veterans need to enroll in a state cannabis program.
Medicare, Medicaid, and VA Policies
Medicare has no pathway for reimbursing medical cannabis purchased at a dispensary. The Centers for Medicare and Medicaid Services does allow a narrow pilot program involving federally legal hemp products (those containing no more than 0.3% THC), where certain participating providers can furnish hemp-derived products worth up to $500 per year to eligible beneficiaries. But this program is limited, does not include inhalable products, and explicitly operates within the 2018 Farm Bill’s definition of hemp. It is not a medical marijuana benefit.
Medicaid follows the same federal logic. Even in states where medical marijuana is fully legal, the state Medicaid program will not reimburse dispensary purchases because Medicaid is jointly funded by state and federal dollars, and federal funding cannot be used for Schedule I substances.
The VA’s policy is among the strictest. Clinicians within the VA system are limited to prescribing FDA-approved medications only. Veterans who use medical marijuana through a state program do so entirely on their own, without VA financial support or clinical documentation.
FDA-Approved Cannabinoid Drugs That May Be Covered
There is an important exception to the “no coverage” rule, and it involves a handful of prescription medications that contain cannabinoid compounds but have gone through the full FDA approval process. These are not the same as buying flower or edibles from a dispensary. They are pharmaceutical products prescribed for specific conditions, manufactured under FDA oversight, and dispensed by regular pharmacies.
The three you’re most likely to encounter:
- Epidiolex (cannabidiol): approved for certain types of severe epilepsy
- Dronabinol (sold as Marinol or Syndros): a synthetic form of THC approved for chemotherapy-related nausea and AIDS-related weight loss
- Nabilone (sold as Cesamet): another synthetic cannabinoid for chemotherapy-related nausea
Some Medicare Part D plans, Medicare Advantage plans, and private insurance formularies cover these medications for their approved uses. Coverage varies by plan, and you may face prior authorization requirements or step therapy (meaning your insurer requires you to try other treatments first). If your doctor prescribes one of these, check your plan’s formulary or call your insurer directly to confirm coverage and out-of-pocket costs.
You Can’t Use an HSA or FSA Either
If you have a Health Savings Account, Flexible Spending Account, or Health Reimbursement Arrangement, you might assume you could use those tax-advantaged funds to pay for medical marijuana. You can’t. The IRS is clear on this point: expenses for controlled substances that aren’t legal under federal law cannot be included as medical expenses, even if your state has legalized them. This rule appears directly in IRS Publication 502, which governs medical and dental expense deductions. Using HSA or FSA money on dispensary cannabis could trigger tax penalties.
What You’ll Actually Pay Out of Pocket
Since insurance won’t help, the full cost of medical marijuana falls on you. The expenses break down into two categories: getting certified and buying the product itself.
Certification costs vary widely by state. You’ll typically need an evaluation from a physician who can confirm you have a qualifying condition and provide the documentation your state requires. These appointments often cost between $100 and $300, and most states require annual renewals. On top of that, many states charge a fee for the medical marijuana identification card itself. In Los Angeles County, for example, the card application fee is $100 for a patient without a caregiver and $200 if you designate one caregiver.
Product costs at dispensaries depend on what you’re buying, how often, and where you live. Monthly spending for regular users commonly ranges from $100 to $300 or more, though this varies enormously based on dosage, product type (flower, tinctures, edibles, concentrates), and local pricing. Some states offer reduced fees or tax exemptions for medical cardholders compared to recreational buyers, which can offset part of the cost.
Could Rescheduling Change Things?
There has been serious discussion at the federal level about moving marijuana from Schedule I to Schedule III, which would place it alongside drugs like testosterone and certain codeine formulations. If that happens, one of the most significant downstream effects could involve insurance. Unlike Schedule I substances, Schedule III drugs can qualify for insurance reimbursement under certain conditions, depending on FDA approval status and established clinical uses.
Rescheduling alone, however, would not automatically mean your insurer starts covering dispensary cannabis. Insurers would still likely require FDA approval for specific products and conditions before adding them to formularies. What rescheduling would do is remove the legal barrier that currently makes coverage impossible. From there, insurers could begin implementing coverage with the same tools they use for other controlled substances: prior authorization, step therapy, formulary restrictions, and clinical criteria.
In practical terms, rescheduling would open a door that is currently locked. Walking through it would still require FDA action on specific cannabis products, followed by individual insurer decisions about what to cover and for whom. That process, if it happens, would take years to play out across the insurance landscape.